Home / Share Price Target / Glaxo
Glaxosmithkline Share Price Target 2024, 2025, 2026 to 2039 With Charts
GlaxoSmithKline Pharmaceuticals Limited | |||
 | Symbol: GLAXO | ||
| Price: ₹2,369.64 | |||
| Exchange: NSE | |||
| Healthcare -> Drug Manufacturers - General | |||
Show Table of Contents
Table of Contents
- 1: Glaxosmithkline Brief Company Overview
- 1.1: Company Overview
- 1.2: Glaxosmithkline Financial Performance
- 1.2.1: Is Glaxosmithkline A Good Buy For Long Term?
- 2: Approach 1: Technical Analysis Paired With Price Action
- 2.1: Glaxosmithkline Share Price Target For 2024
- 2.1.1: Glaxosmithkline Share Price Target Table For 2024
- 2.1.2: Summary: Glaxosmithkline Share Price Prediction For 2024
- 2.2: Glaxosmithkline Share Price Target For 2025
- 2.2.1: Glaxosmithkline Share Price Target Table For 2025
- 2.2.2: Summary: Glaxosmithkline Share Price Prediction For 2025
- 3: Approach 2: Machine Learning By Studying Historical Prices
- 3.1: Glaxosmithkline Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
- 3.2: Glaxosmithkline Share Price Target Table From 2024, 2025, 2026 to 2039
- 4: Glaxosmithkline Past Performance
Glaxosmithkline Brief Company Overview
Company Overview
GlaxoSmithKline Pharmaceuticals Limited, headquartered in Mumbai, India, is a leading manufacturer and distributor of pharmaceuticals.
Founded in 1924, the company offers a diverse range of products, including:
- Vaccines and specialty medicines
- Antibiotics and general medicines
- Products for infectious diseases, HIV, oncology, and immunology
With a strong reputation in the industry, the company is committed to delivering innovative and effective healthcare solutions.
Glaxosmithkline Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 44,219.27 Crore | Market valuation of Glaxosmithkline's shares. |
| Revenue (TTM) | 3,560.47 Crore | Total revenue generated by Glaxosmithkline over the past twelve months. |
| Net Income (TTM) | +675.03 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 30.15% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 18.95% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) | +5.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) | +16.1% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio | 0.88 | Company's total debt divided by total shareholder equity. |
| Total Debt | 14.79 Crore | Sum of Glaxosmithkline's current & long-term financial obligations. |
| Total Cash | 2,110.82 Crore | Total amount of liquid funds available to Glaxosmithkline. |
| Beta | 0.18 | Beta is less than 1 indicating that the Glaxosmithkline's price is less volatile than the market. |
Is Glaxosmithkline A Good Buy For Long Term?
GlaxoSmithKline (GSK) presents a mixed picture for long-term investment. While its 72.63% return over the past 12 months and strong 5-year performance (71.33%) are encouraging, a recent 10.02% drop in the past three months warrants caution. The company boasts a healthy profit margin of 18.95% and substantial cash reserves (₹2,110.82 Crore), offsetting a relatively small debt of ₹14.79 Crore (Q2 2024-25). Considering the recent volatility and positive long-term trends, GSK is an average buy for long-term investors with a moderate risk tolerance.
To predict the Glaxosmithkline's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Glaxosmithkline Share Price Target For 2024
The line chart displays the monthly closing prices of Glaxosmithkline with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glaxosmithkline shares in 2024, see the table below.
Glaxosmithkline Share Price Target Table For 2024
| Glaxosmithkline's Levels | Value | Reason/Importance |
|---|---|---|
| 2024 Target 3 | 2446.30 (+3.23%) | Price Action: Nov 2024 High |
| 2024 Target 2 | 2414.05 (+1.87%) | Price Action: 19 Nov 2024 Low |
| 2024 Target 1 | 2388.84 (+0.81%) | Custom Fibonacci Extension Lvl 23.6% |
| Current Price | 2369.64 | Glaxosmithkline's 1 share price as of Thu 21 Nov 2024 |
| Stop Loss 1 | 2363.74 (-0.25%) | Price Action: Chart |
| Stop Loss 2 | 2332.40 (-1.58%) | Fibonacci Retracement Extended 40% |
| Stop Loss 3 | 2297.74 (-3.04%) | Fibonacci Retracement Extended 82.6% |
Summary: Glaxosmithkline Share Price Prediction For 2024
In summary, Glaxosmithkline has surged by ₹471.49, achieving a notable +24.84% increase from 1st January 2024 to 21 Nov 2024. Our analysis of Glaxosmithkline for 2024 predicts an additional rise of 0.81% to 3.23% by the end of 2024 with three potential targets T1: 2388.84, T2: 2414.05, T3: 2446.30. Stop Loss at SL1: 2363.74, SL2: 2332.40, SL3: 2297.74.
Glaxosmithkline has a 52-week high of ₹3088.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹1616.90, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's share price prediction, let's now check what 2025 might hold for Glaxosmithkline.
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Glaxosmithkline Share Price Target For 2025
The line chart displays the monthly closing prices of Glaxosmithkline with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Glaxosmithkline shares in 2025, see the table below.
Glaxosmithkline Share Price Target Table For 2025
| Glaxosmithkline's Levels | Value | Reason/Importance |
|---|---|---|
| 2025 Target 3 | 3387.26 (+42.94%) | Price Action: Chart |
| 2025 Target 2 | 3324.10 (+40.27%) | Price Action: Chart |
| 2025 Target 1 | 3291.19 (+38.88%) | Custom Fibonacci Extension Lvl 64.9% |
| Current Price | 2369.64 | Glaxosmithkline's 1 share price as of Thu 21 Nov 2024 |
| Stop Loss 1 | 2137.94 (-9.78%) | Price Action: Apr 2024 High |
| Stop Loss 2 | 2091.05 (-11.76%) | Price Action: Feb 2024 Low |
| Stop Loss 3 | 2053.41 (-13.35%) | Price Action: Chart |
Summary: Glaxosmithkline Share Price Prediction For 2025
In summary, Glaxosmithkline has surged by ₹471.49, achieving a notable +24.84% increase from 1st January 2024 to 21 Nov 2024. Our analysis of Glaxosmithkline for 2025 predicts an additional rise of 38.88% to 42.94% by the end of 2025 with three potential targets T1: 3291.19, T2: 3324.10, T3: 3387.26. Stop Loss at SL1: 2137.94, SL2: 2091.05, SL3: 2053.41.
Glaxosmithkline has a All-Time high of ₹3088.00, acting as a crucial resistance level - a ceiling that could challenge further price increase. Conversely, it has a 52-week low of ₹1616.90, a critical support level - think of this as a safety net where the price might stop falling.
After looking at 2024's and 2025's share price prediction, you might wonder what are short term targets for Glaxosmithkline, we have created a specific page for that check here: Glaxosmithkline Share Price Target For Tomorrow & Next Week
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Glaxosmithkline Long Term Share Price Prediction Chart From 2024, 2025, 2026 to 2039
This chart presents a detailed projection of Glaxosmithkline share price predictions from 2024, 2025, 2026 to 2039. This share price Prediction represents a CAGR of 6.96% over the next 15 years.
For complete year by year Glaxosmithkline long term share price target from 2024, 2025 to 2039 check the below table.
Glaxosmithkline Share Price Target Table From 2024, 2025, 2026 to 2039
| Year | Glaxosmithkline Target | YoY Change % |
|---|---|---|
| 2024 | ₹2,369.64 | [Current Price] |
| 2024 | ₹2,750.01 | 16.05% |
| 2025 | ₹3,109.72 | 13.08% |
| 2026 | ₹3,094.74 | -0.49% |
| 2027 | ₹3,274.44 | 5.8% |
| 2028 | ₹3,848.36 | 17.52% |
| 2029 | ₹4,122.93 | 7.13% |
| 2030 | ₹4,521.3 | 9.66% |
| 2031 | ₹4,382.59 | -3.07% |
| 2032 | ₹4,532.38 | 3.41% |
| 2033 | ₹5,221.3 | 15.19% |
| 2034 | ₹5,495.87 | 5.25% |
| 2035 | ₹5,932.87 | 7.95% |
| 2036 | ₹5,670.44 | -4.43% |
| 2037 | ₹5,790.31 | 2.11% |
| 2038 | ₹6,594.23 | 13.88% |
| 2039 | ₹7,053.37 | 6.96% |
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Glaxosmithkline Past Performance
- In 1990, Glaxosmithkline opening price was ₹45.45
- As of Thu 21 Nov 2024 the price stands at ₹2,369.64.
- This represents a Compound Annual Growth Rate (CAGR) of 11.96%.
- In 34 years, an investment of 10,000 would have become ₹5.21 Lakh.
As we wrap up, we hope you like our study on Glaxosmithkline share price predictions, please kindly note that these forecasts are based on technical analysis, past trends, and machine learning models. They are for educational purposes only, not investment advice.
Show Methodology We Use
Methodology Behind the Prediction
The share price predictions present on our site are derived from a robust model that incorporates multiple economic indicators, technical indicators, company performance metrics, and industry-specific factors.
We have historical share price data of all stocks for which we present targets, so we analyse historical trends from those past data and overlay them with projected market conditions to estimate future share prices of a stock.
- Glaxosmithkline Share Price History
- Glaxosmithkline Price Target Tomorrow
- Glaxosmithkline Dividend History
- Glaxosmithkline Bonus History
Disclaimer: Information is provided 'as is' and solely for informational and educational purposes, not for trading purposes or advice. We highly recommend to do your own research before making any investment.
